Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan (Q39496571)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

12 September 2017

Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan (English)

1 reference

Europe PubMed Central

12 September 2017

Helicobacter pylori

0 references

(RS)-rabeprazole

0 references

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27213463%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Mitsushige Sugimoto

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27213463%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Shu Sahara

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27213463%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Hitomi Ichikawa

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27213463%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Hiromitsu Ban

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27213463%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Taketo Otsuka

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27213463%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Akira Andoh

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27213463%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Takahisa Furuta

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27213463%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

23 May 2016

1 reference

Europe PubMed Central

12 September 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27213463%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27213463%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27213463%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Furazolidone-based triple therapy for H pylori gastritis in children

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Role of bismuth in improving Helicobacter pylori eradication with triple therapy

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan.

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin.

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

High Helicobacter pylori cure rate with sitafloxacin-based triple therapy

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

The life and death of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin

1 reference

https://api.crossref.org/works/10.1111%2FHEL.12319

21 January 2018

Identifiers

10.1111/HEL.12319

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27213463%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

release_kvqary63dnb53fsw5axnor5jdq

1 reference

https://api.fatcat.wiki/v0/release/kvqary63dnb53fsw5axnor5jdq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27213463%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39496571&oldid=1843283318"